Croma Exprecell

What is Exprecell?

Exprecell is a new generation medical device for the preparation of autologous Platelet-Rich Plasma (PRP) and Fluid-Platelet-Rich Fibrin (Fluid-PRF). Developed by Croma-Pharma, the system is MDR-approved and designed to support clinicians who are offering regenerative treatments such as PRP. With a growing interest in regenerative approaches, Exprecell provides
practitioners with an efficient and reliable way to prepare autologous blood concentrates within clinical practice.

What makes the Exprecell system different from other PRP preparation systems?

Exprecell is currently one of the only MDR approved devices labelled for both PRP and Fluid-PRF preparation. The innovative, all in-one design has been developed to allow both blood aspiration and preparation within a high capacity single syringe device. After collecting the blood sample, the system uses an optimised separation process with a single spin. This allows PRP to be prepared from whole blood in approximately five minutes of
spin time. The design simplifies the preparation process for clinicians while supporting efficient and consistent results.


The system also prepares PRP without anticoagulants. Why is this important?

The preparation of PRP without the use of anticoagulants results in the formation of Fluid-PRF. This is a biologically active concentrate that retains the regenerative properties of platelets and leukocytes while remaining liquid for a defined period of time. Maintaining this liquid state allows clinicians to use the preparation during treatment while preserving the biological components that are important in regenerative medicine.

What are the benefits of using Exprecell?

Exprecell has been designed with efficiency and usability in mind. The high-capacity syringe allows clinicians to aspirate approximately 18ml of whole blood, which yields around 8.5ml of autologous PRP or Fluid-PRF. The single spin preparation process takes about five minutes, helping to streamline treatment workflows.

Data from the system shows that platelet concentration reaches approximately 2.3-fold above baseline levels. This level falls within the optimal range often targeted in PRP preparations. At the same time, the system reduces erythrocytes by around 99 percent and leukocytes by approximately 95 percent. Platelet recovery has been observed between 52 percent and 96 percent. The preparation also contains extracellular vesicles (86% of which are platelet-derived), including exosomes, with around 7.5 million EVs per millilitre.

As one of the first practitioners to offer this system in the UK, what does this launch mean for your practice?

I have utilised PRP alongside non-surgical and surgical procedures to address hair loss and having trialled it, I am proud to be one of the first practitioners to offer Exprecell in the UK. With the growing patient demand for regenerative treatments, it is exciting to provide an MDR-approved solution for autologous Platelet-Rich Plasma and Fluid-Platelet-Rich Fibrin. It allows clinicians to offer regenerative treatments using an efficient preparation system that aligns with modern medical standards.


Dr Munir Somji is an Aesthetic Surgeon, and the CMO and founder of Dr MediSpa in London. The clinic was one of the first to offer surgical and non-surgical treatments under one roof. He is listed by RealSelf in the Top 100 cosmetic surgeons worldwide.